FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Treatment Tolerability and Toxicity of Postoperative Proton Beam Therapy for Gynecologic Malignancies: Results of the Prospective Phase 2 APROVE Trial. PMID 36642110 · Int J Radiat Oncol Biol Phys · 2023-Jul-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| PSMA-PET/CT-Guided Intensification of Radiation Therapy for Prostate Cancer (PSMAgRT): Findings of Detection Rate, Effect on Cancer Management, and Early Toxicity From a Phase 2 Randomized Controlled Trial. PMID 36639035 · Int J Radiat Oncol Biol Phys · 2023-Jul-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Five-Year Patient-Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer. PMID 36592721 · Int J Radiat Oncol Biol Phys · 2023-Jul-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Development and validation of competitive risk model for older women with metaplastic breast cancer. PMID 37452414 · BMC Womens Health · 2023-Jul-14 The record describes a retrospective prognostic model study using SEER registry data, not a clinical trial report. It lacks explicit Phase III/IIIb or Phase II/III designation, a drug-containing intervention, and a primary/key secondary time-to-event efficacy endpoint from a randomized controlled trial. The publication type 'Randomized Controlled Trial' appears to be a metadata error not supported by the abstract content. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| A novel nomogram and risk stratification system predicting the cancer-specific survival of patients with gastric neuroendocrine carcinoma: a study based on SEER database and external validation. PMID 37452300 · BMC Gastroenterol · 2023-Jul-14 The record is an oncology retrospective cohort study developing a nomogram for cancer-specific survival. It is not a randomized trial (despite the 'Randomized Controlled Trial' publication type tag, which appears to be a misclassification for the internal random assignment of the SEER data into training/validation sets), has no indicated phase, and does not test a drug intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of doxycycline versus iodopovidone for pleurodesis through an intercostal tube in malignant pleural effusions: a randomized trial. PMID 37428348 · Support Care Cancer · 2023-Jul-10 The study is a randomized trial in oncology patients with a drug intervention, but the primary endpoint is the success rate at 30 days (a categorical efficacy outcome), not a time-to-event endpoint like OS, PFS, DFS, EFS, RFS, or TTP. No Kaplan-Meier or hazard ratio results are reported. The phase is not explicitly stated in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16). PMID 36753698 · J Clin Oncol · 2023-Jul-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Nomogram for predicting the likelihood of liver metastases at initial diagnosis in patients with Siewert type II gastroesophageal junction adenocarcinoma. PMID 37419904 · Sci Rep · 2023-Jul-07 The record describes a retrospective, non-randomized, non-interventional study that builds a predictive nomogram for liver metastases in gastroesophageal junction adenocarcinoma using SEER database patients. It is not a Phase III/IIIb or Phase II/III randomized controlled trial of a drug-containing intervention with a primary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Best first-line therapy for people with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status. PMID 37419867 · Cochrane Database Syst Rev · 2023-Jul-07 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Study protocol: randomised controlled trial of conditioned open-label placebo (COLP) for perioperative pain management in patients with head and neck cancer. PMID 37419646 · BMJ Open · 2023-Jul-07 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| The effect of aminolevulinic acid hydrochloride topical powder photodynamic therapy versus nocardia rubra cell wall skeleton and observers group in the treatment of cervical low-grade squamous intraepithelial lesions with human papillomavirus infection: A non-randomized study, controlled pilot study. PMID 37417604 · Medicine (Baltimore) · 2023-Jul-07 The record describes a non-randomized, controlled pilot study comparing two therapies (ALA-PDT vs. Nr-CWS) for cervical LSIL/HPV. It is not a Phase III/IIIb or Phase II/III randomized trial, and it lacks a drug-containing intervention as defined (photodynamic therapy and immunotherapy are not typical drug interventions). The primary efficacy endpoints are categorical (clearance/remission rates), not time-to-event measures like OS or PFS, and no Kaplan-Meier or HR data is reported. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS). PMID 36999560 · Br J Dermatol · 2023-Jul-07 The study is a Phase III randomized trial of a drug (baricitinib) for atopic dermatitis, which is a non-oncologic inflammatory skin condition, not a malignant neoplasm. The primary and key secondary endpoints are categorical response rates (e.g., vIGA, EASI, SCORAD) and continuous mean changes, not time-to-event efficacy endpoints like OS, PFS, DFS, or Kaplan-Meier curves with hazard ratios. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer. PMID 37407274 · Cochrane Database Syst Rev · 2023-Jul-05 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| The EMA Assessment of Asciminib for the Treatment of Adult Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Who Were Previously Treated With at Least Two Tyrosine Kinase Inhibitors. PMID 37141403 · Oncologist · 2023-Jul-05 The report is an eligible Phase III randomized drug-intervention oncology trial, but it does not meet the required time-to-event efficacy endpoint criterion. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer. PMID 37134294 · Oncologist · 2023-Jul-05 The study is a randomized, drug-intervention trial in oncology, but it is not a Phase III/IIIb or definitive Phase II/III trial. More critically, the primary outcome is 'time to treatment failure' (TTF), which is not one of the standard time-to-event efficacy endpoints (OS, PFS, DFS, EFS, RFS, TTP) specified for inclusion, and no Kaplan-Meier analysis or hazard ratio is reported. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Cytochrome P450 Oxidoreductase (POR) Associated with Severe Paclitaxel-Induced Peripheral Neuropathy in Patients of European Ancestry from ECOG-ACRIN E5103. PMID 37126018 · Clin Cancer Res · 2023-Jul-05 The record is a pharmacogenomic analysis of a toxicity endpoint (paclitaxel-induced peripheral neuropathy) from a phase III trial. While it is from an oncology RCT with a drug intervention, it does not report a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, etc.), Kaplan-Meier data, or hazard ratios. The study is a biomarker-focused subgroup analysis, not the primary efficacy report. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma. PMID 37093199 · Clin Cancer Res · 2023-Jul-05 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Patient Understanding of Oncology Clinical Trial Endpoints in Direct-to-Consumer Television Advertising. PMID 37079495 · Oncologist · 2023-Jul-05 The record describes a randomized study on patient understanding of clinical trial endpoints in advertising, not a clinical trial of an oncology drug. It lacks the required elements: a real drug intervention in a Phase III/IIIb or II/III setting, and original time-to-event efficacy results (e.g., Kaplan-Meier, HR) from that trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials. PMID 37058234 · Clin Cancer Res · 2023-Jul-05 The record is an updated formal result of two randomized Phase II/III trials (STAMP and STRIDE) evaluating a drug combination for an oncology indication, with OS as the primary endpoint. The specific trial phases (Phase II/III) are referenced in the trial identifiers (NCT01487863, NCT01981122) but are not explicitly stated in the provided abstract text. Eligibility cannot be definitively established without explicit confirmation of the phase being Phase III/IIIb or Phase II/III from the provided metadata, hence is_eligible is set to null. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Triple modal treatment comprising with proton beam radiation, hyperthermia, and gemcitabine/nab-paclitaxel for locally advanced pancreatic cancer: a phase I/II study protocol (TT-LAP trial). PMID 37403011 · BMC Cancer · 2023-Jul-04 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Fosaprepitant Weekly vs Every 3 Weeks for the Prevention of Concurrent Chemoradiotherapy-Induced Nausea and Vomiting: A Pilot Randomized Clinical Trial. PMID 37498596 · JAMA Netw Open · 2023-Jul-03 The report describes a pilot randomized trial without explicit confirmation of a Phase III/IIIb or Phase II/III design. The primary endpoint is not a time-to-event efficacy endpoint (it is a proportion), though a secondary endpoint (PFS) is time-to-event. The lack of a definitive Phase III designation prevents eligibility. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Baseline Features and Reasons for Nonparticipation in the Colonoscopy Versus Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM) Study, a Colorectal Cancer Screening Trial. PMID 37432690 · JAMA Netw Open · 2023-Jul-03 The study is a randomized trial in oncology (colorectal cancer screening) with human participants, but it lacks a drug-containing intervention (comparing colonoscopy vs. FIT) and the reported analysis does not present a time-to-event efficacy endpoint (OS, PFS, etc.) with Kaplan-Meier or HR data. This is a descriptive analysis of baseline features and nonparticipation reasons, not the primary efficacy results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Enhancing educational and vocational recovery in adolescents and young adults with early psychosis through Supported Employment and Education (SEEearly): study protocol for a multicenter randomized controlled trial. PMID 37400899 · Trials · 2023-Jul-03 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Development and validation of prognostic nomograms based on De Ritis ratio and clinicopathological features for patients with stage II/III colorectal cancer. PMID 37400788 · BMC Cancer · 2023-Jul-03 The study is an observational, retrospective prognostic model development and validation study. It does not involve a randomized comparison of a drug-containing intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Identification of cuproptosis-related lncRNA for predicting prognosis and immunotherapeutic response in cervical cancer. PMID 37400520 · Sci Rep · 2023-Jul-03 The record is an original research article presenting a biomarker signature derived from retrospective data. While it analyzes progression-free survival (time-to-event) and mentions random assignment to training/test groups for model building, it is not a report of a randomized controlled trial. There is no evidence of a phase III/IIIb or phase II/III trial, and the study does not evaluate a drug-containing intervention arm as its primary focus. The drug intervention signal is weak as it only explores sensitivity predictions. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Unresectable hepatocellular carcinoma: transarterial chemoembolisation plus Huachansu - a single-center randomised controlled trial. PMID 37400162 · BMJ Support Palliat Care · 2023-Jul-03 The study is a randomized trial with primary efficacy endpoints (PFS, OS) in oncology. However, the intervention (TACE plus Huachansu) is not considered a drug-containing regimen for eligibility, as Huachansu is a traditional Chinese medicine and TACE is a procedure, not a drug. Additionally, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the abstract or metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Digital therapeutic to improve cancer-related well-being: a pilot randomized controlled trial. PMID 37321673 · Int J Gynecol Cancer · 2023-Jul-03 This is a pilot randomized controlled trial in oncology with human patients and reports original results. However, it is not a Phase III/IIIb or Phase II/III trial (it is a pilot study), it does not have a drug-containing intervention (the intervention is a digital therapeutic app), and it lacks a primary or key secondary time-to-event efficacy endpoint (such as OS, PFS, DFS, etc.). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A prospective randomized controlled trial evaluating the safety and efficacy of patient blood management program in patients with gynecologic cancer (KGOG 4011/PBM). PMID 37094968 · Int J Gynecol Cancer · 2023-Jul-03 This is a protocol for a randomized trial (NCT05669872) evaluating a patient blood management (iron supplementation) program in gynecologic cancer patients. The primary endpoint is the rate of transfusion within 3 weeks after surgery, which is not a time-to-event efficacy endpoint. No time-to-event signals (OS, PFS, DFS, etc., Kaplan-Meier, HR) are reported. The study phase is not specified as III/IIIb or II/III. The record describes the trial design but does not present results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Deciphering the mechanisms of action of progesterone in breast cancer. PMID 37395734 · Oncotarget · 2023-Jul-01 The record describes a randomized controlled trial in breast cancer with a drug intervention and time-to-event endpoints, but the publication is a 'research perspective' summarizing evidence and mechanistic studies, not a primary formal-result report of the trial itself. The trial phase is also not explicitly confirmed in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer. PMID 37379691 · J Clin Oncol · 2023-Jul-01 The record is excluded because the trial phase (Phase III/IIIb or Phase II/III) is not explicitly established in the provided abstract or metadata. All other key criteria (oncology, human, randomized, time-to-event endpoint, drug intervention, original result) are met. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. PMID 37200022 · JAMA Oncol · 2023-Jul-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Long-Term Outcomes of TROG 13.01 SAFRON II Randomized Trial of Single- Versus Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases. PMID 37179526 · J Clin Oncol · 2023-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effects of Specialist Palliative Care for Patients Undergoing Major Abdominal Surgery for Cancer: A Randomized Clinical Trial. PMID 37163249 · JAMA Surg · 2023-Jul-01 The record describes a randomized trial in oncology with a time-to-event primary efficacy endpoint, but the intervention is a non-drug palliative care service, which fails the drug-intervention criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Acute Lymphoblastic Leukemia Intercontinental-Berlin-Frankfurt-Münster 2009 Trial. PMID 37141547 · J Clin Oncol · 2023-Jul-01 The record is an original result report of a randomized trial in pediatric oncology (ALL) evaluating drug interventions (chemotherapy regimens with methotrexate) with primary time-to-event endpoints (EFS, OS). However, the explicit trial phase (e.g., Phase III) is not stated in the provided metadata (title, abstract, publication types, MeSH). Without clear evidence of Phase III/IIIb or Phase II/III, eligibility cannot be confirmed as per the criteria requiring explicit establishment of all criteria. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Bacterial Decolonization for Prevention of Radiation Dermatitis: A Randomized Clinical Trial. PMID 37140904 · JAMA Oncol · 2023-Jul-01 The record describes a randomized trial in oncology patients but is excluded because (1) the intervention is non-drug-only, and (2) the primary endpoint is not time-to-event. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial. PMID 37126762 · J Clin Oncol · 2023-Jul-01 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Breast Cancer Recurrence by Subtype in a Diverse, Contemporary Cohort of Young Women. PMID 37052317 · J Am Coll Surg · 2023-Jul-01 The record is a retrospective cohort study analyzing recurrence patterns, not a randomized trial of a drug intervention. The metadata incorrectly tags it as a 'Randomized Controlled Trial'. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Single-photon emission computed tomography-defined active bone marrow-sparing volumetric-modulated arc therapy reduces the incidence of acute hematologic toxicity in locally advanced cervical cancer patients who receive chemoradiotherapy: A single-center prospective randomized controlled trial. PMID 37043337 · Cancer · 2023-Jul-01 The trial meets criteria for oncology, human, randomized, drug intervention, and original result. It reports time-to-event endpoints. However, the definitive trial phase (Phase III/IIIb or Phase II/III) is not established from the provided metadata, and the primary endpoint is a safety/toxicity endpoint, not a primary/key secondary time-to-event efficacy endpoint as required for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| BRACHY: A Randomized Trial to Evaluate Symptom Improvement in Advanced Non-Small Cell Lung Cancer Treated With External Beam Radiation With or Without High-Dose-Rate Intraluminal Brachytherapy. PMID 36610615 · Int J Radiat Oncol Biol Phys · 2023-Jul-01 The trial is randomized and reports time-to-event efficacy endpoints, but it lacks a drug-containing intervention. It is a radiotherapy-only comparison. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Intraoperative Fluorescence Guidance for Breast Cancer Lumpectomy Surgery. PMID 38320161 · NEJM Evid · 2023-Jul 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Brief intervention to enhance cessation of smokeless tobacco use in newly diagnosed patients with head and neck cancers: A randomized controlled trial in patient-relative dyads. PMID 37645365 · Indian J Psychiatry · 2023-Jul The study is a randomized trial in oncology patients with primary results, but it is excluded because it does not meet the core eligibility criteria: 1) The intervention is behavioral (tobacco cessation), not a drug-containing intervention; 2) The primary endpoints are cessation rates at fixed timepoints (1-month and 3-month follow-ups), reported as relative risks and odds ratios, not a primary or key secondary time-to-event efficacy endpoint (such as OS, PFS, DFS, etc.) analyzed with Kaplan-Meier methods or reporting a hazard ratio. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation. PMID 37479483 · J Immunother Cancer · 2023-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Half-Dose Gadopiclenol versus Full-Dose Gadobutrol for Contrast-enhanced Body MRI. PMID 37462494 · Radiology · 2023-Jul 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
H
L
B
|
旧查询独有 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| Short-term anti-TNF therapy with surgical closure versus anti-TNF therapy alone for Crohn's perianal fistulas (PISA-II): long-term outcomes of an international, multicentre patient preference, randomised controlled trial. PMID 37457118 · EClinicalMedicine · 2023-Jul The study is a randomized controlled trial in Crohn's disease (non-oncology), evaluating anti-TNF therapy ± surgical closure for perianal fistulas. The primary endpoint is radiological healing (binary outcome), not a time-to-event endpoint (e.g., OS, PFS, DFS). Therefore, it does not meet the required oncology or time-to-event efficacy endpoint criteria. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Cicaderma® in radiation-related dermatitis of breast cancer: Results from the multicentric randomised phase III CICA-RT. PMID 37441546 · Clin Transl Radiat Oncol · 2023-Jul The study is an oncology randomized phase III trial with original results, but it does not meet the core eligibility criteria: it lacks a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) and lacks a drug-containing intervention (Cicaderma® is a topical non-drug product, and the comparator is standard non-drug care). The primary endpoint is prevention of radiation dermatitis, which is a toxicity/safety outcome, not an efficacy endpoint. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Longitudinal trajectory of quality of life for patients with melanoma brain metastases: A secondary analysis from a whole brain radiotherapy randomized clinical trial. PMID 37441544 · Clin Transl Radiat Oncol · 2023-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Photodynamic Diagnosis-guided Transurethral Resection of Bladder Tumour in Participants with a First Suspected Diagnosis of Intermediate- or High-risk Non-muscle-invasive Bladder Cancer: Cost-effectiveness Analysis Alongside a Randomised Controlled Trial. PMID 37441343 · Eur Urol Open Sci · 2023-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Cardiovascular Implications of Vascular Endothelial Growth Factor Inhibition Among Adolescents/Young Adults in ECOG-ACRIN E2805. PMID 37433436 · J Natl Compr Canc Netw · 2023-Jul The study is a retrospective analysis of cardiovascular events (LVSD and hypertension) from the randomized ASSURE trial. While it involves oncology, human subjects, randomization, and drug intervention, it does not report a time-to-event efficacy endpoint (OS, PFS, DFS, etc.) as required. The primary outcomes are incidence of adverse events, not survival or disease progression. The phase is not explicitly confirmed in the text (though ASSURE is Phase III, we cannot infer from drug names). Therefore, it is not eligible for inclusion in the oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results. PMID 37429923 · Nat Med · 2023-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non-muscle-invasive Bladder Cancer (BRIDGE). PMID 37422371 · Eur Urol Focus · 2023-Jul The record describes the design and rationale of a Phase 3 randomized trial in human oncology with a drug intervention, but does not report any time-to-event efficacy results, Kaplan-Meier curves, or hazard ratios. Therefore, eligibility cannot be determined. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |